<DOC>
	<DOCNO>NCT00243386</DOCNO>
	<brief_summary>The primary purpose randomize , two-arm parallel clinical study 66 previously treat patient severe moderately severe hemophilia A compare rate bleed episode standard prophylaxis ( 20-40 IU/kg every 48 ± 6 hour ; actual dose determine investigator ) alternate prophylaxis ( 20-80 IU/kg every 72 + 6 hour ; actual dose determine Baxter utilize algorithm patient 's pharmacokinetic data ) . The rate bleed episode on-demand regimen prophylaxis regimen also compare cross-over portion study . Enrolled patient treat originally demand period 6 month randomize one prophylaxis arm . Prophylactic treatment last period 12 month +/- 2 week .</brief_summary>
	<brief_title>Prophylaxis Study Recombinant Factor VIII Manufactured Protein-Free ( rAHF-PFM ) Patients With Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>The subject severe moderately severe hemophilia A defined baseline factor VIII level &lt; = 2 % normal , test screen The subject document history least 150 exposure day factor VIII concentrate ( either plasmaderived recombinant ) The subject within 7 65 year age The subject Karnofsky performance score &gt; ( great ) 60 The subject human immunodeficiency virus negative ( HIV ) HIV+ CD4 count &gt; = 400 cells/mm³ ( CD4 count determine screening , necessary ) The subject document ondemand treatment regimen least 12 month immediately prior enrollment The subject document history ( e.g . medical chart dispense information , sign investigator statement ) least 8 joint hemorrhage 12 month immediately prior enrollment The subject reside within coverage area mobile compliance device ; coverage area determine screen The subject subject 's legally authorize representative provide write informed consent The subject know hypersensitivity factor VIII concentrate mouse hamster proteins The subject history factor VIII inhibitor titer &gt; = 0.6 BU ( Bethesda Nijmegen assay ) time prior screen The subject detectable factor VIII inhibitor screening , titer &gt; = 0.4 BU ( Nijmegen Assay ) central laboratory The subject severe chronic liver disease evidence , limited , follow : International Normalized Ratio ( INR ) &gt; 1.4 , hypoalbuminemia , portal vein hypertension include presence otherwise unexplained splenomegaly history esophageal varix . The subject diagnose inherit acquire hemostatic defect hemophilia A ( e.g. , qualitative platelet defect von Willebrand 's Disease ) The subject treat last sixty ( 60 ) day prior treat screening/enrollment immunomodulating drug . The subject participate another investigational study within thirty ( 30 ) day enrollment The subject previously participate clinical study rAHFPFM The subject 's clinical condition may require major surgery ( define moderate critical risk perioperative blood loss ≥ 500 mL ) period subject 's participation study The subject female childbearing potential positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>